Am I missing anything? Is this the right decision?

Can I show this data?

Am I too late?

Find clarity in your investment decision-making.

Manage your portfolio for sustainable growth

and regulatory alignment

with the ultimate blend of powerful AI and

industry expertise.

Reduce risk, meet your sustainability goals and push the boundaries of possibilities based on

facts, not opinions.

Clarity AI scaling human decisions through tech.

Visit clarity.

And take action today.

It's November, and the FT's global pharmaceutical editor Hannah Kuchler is in Copenhagen.

She's visiting the headquarters of the drugmaker Novo Nordisk.

So this company is changing the world and I wanted to go to

Copenhagen to see its headquarters to see how the scientists have created these

Wonder Drugs, Zempik and Wigovey, and what they plan to do next.

Both of these drugs, the popular diabetes treatment Ozempick, and Wigovey, which was formulated strictly for weight loss, have had a remarkable run recently.

But when Hannah gets to Novo Nordisk's labs, she says that the place where scientists are developing successors to these blockbuster medications looks quite unassuming from the outside.

So I entered through automatic double doors and it's quite overwhelming on the ground floor. We went upstairs and we walked down this

incredibly long white, dramatically white corridor and going off these corridors are these very small

...